世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
神経学的バイオマーカー市場。世界の産業動向、シェア、サイズ、成長、機会、予測2021-2026年Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global neurological biomarkers market grew at a CAGR of around 15% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind t... もっと見る
サマリーThe global neurological biomarkers market grew at a CAGR of around 15% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments. The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, application and end use. Breakup by Type: Genomic Biomarkers Proteomic Biomarkers Metabolomic Biomarkers Imaging Biomarkers Others Breakup by Application: Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Autism Spectrum Disorders Others Breakup by End Use: Hospital Laboratories Clinical Diagnostic Centers Research Organizations Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm, Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc. Key Questions Answered in This Report: How has the global neurological biomarkers market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global neurological biomarkers market? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the application? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global neurological biomarkers market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Neurological Biomarkers Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Type 6.1 Genomic Biomarkers 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Proteomic Biomarkers 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Metabolomic Biomarkers 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Imaging Biomarkers 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Others 6.5.1 Market Trends 6.5.2 Market Forecast 7 Market Breakup by Application 7.1 Alzheimer's Disease 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Parkinson's Disease 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Multiple Sclerosis 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Autism Spectrum Disorders 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospital Laboratories 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Clinical Diagnostic Centers 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Research Organizations 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Acumen Pharmaceuticals Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.3 Athena Diagnostics (Quest Diagnostics) 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.4 Banyan Biomarkers Inc. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.5 Bio-Rad Laboratories Inc. 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Immunarray Pvt. Ltd. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.) 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Proteome Sciences Plc 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Thermo Fisher Scientific Inc. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis
SummaryThe global neurological biomarkers market grew at a CAGR of around 15% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments. The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, application and end use. Breakup by Type: Genomic Biomarkers Proteomic Biomarkers Metabolomic Biomarkers Imaging Biomarkers Others Breakup by Application: Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Autism Spectrum Disorders Others Breakup by End Use: Hospital Laboratories Clinical Diagnostic Centers Research Organizations Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm, Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc. Key Questions Answered in This Report: How has the global neurological biomarkers market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global neurological biomarkers market? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the application? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global neurological biomarkers market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Neurological Biomarkers Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Type 6.1 Genomic Biomarkers 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Proteomic Biomarkers 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Metabolomic Biomarkers 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Imaging Biomarkers 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Others 6.5.1 Market Trends 6.5.2 Market Forecast 7 Market Breakup by Application 7.1 Alzheimer's Disease 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Parkinson's Disease 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Multiple Sclerosis 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Autism Spectrum Disorders 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospital Laboratories 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Clinical Diagnostic Centers 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Research Organizations 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Acumen Pharmaceuticals Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.3 Athena Diagnostics (Quest Diagnostics) 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.4 Banyan Biomarkers Inc. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.5 Bio-Rad Laboratories Inc. 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Immunarray Pvt. Ltd. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.) 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Proteome Sciences Plc 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Thermo Fisher Scientific Inc. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
IMARC Services Private Limited.社のその他分野での最新刊レポート
本レポートと同じKEY WORD（biomarkers）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/25 10:26 155.25 円 163.23 円 198.36 円 |
